Comparative Pharmacology
Head-to-head clinical analysis: ACTIQ versus ASTRAMORPH PF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIQ versus ASTRAMORPH PF.
ACTIQ vs ASTRAMORPH PF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Mu-opioid receptor agonist; produces analgesia, sedation, and euphoria by mimicking endogenous endorphins.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Intravenous: 8-10 mg over 2-5 minutes; may be repeated every 8-12 hours as needed. Oral (immediate release): 10-20 mg every 4-6 hours as needed. Oral (extended release): 10-40 mg every 12 hours.
None Documented
None Documented
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Terminal elimination half-life: 2-4 hours; prolonged in renal impairment (up to 12 hours in anuria) and elderly
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Renal: 70-80% unchanged; Biliary/Fecal: 10-20% as metabolites
Category C
Category C
Opioid Analgesic
Opioid Analgesic